I’m a 21-year-old grad, why does the government want me to go on the dole to get a job? July 30, 2026 Oliver Dean was turned away from Job Centre because he wasn’t already on benefit. No wonder the welfare bill is ballooning Andy Burnham’s answer to youth unemployment has arrived. It begins with 14-year-olds, and the new technical pathways reach classrooms in September 2028. There is a great deal to be said for it and, as [...]
Here’s how to fix London listings July 30, 2026 The exodus from the London Stock Exchange demands practical solutions, not complaint, says Jonathan Dickson This week DCC Energy became the latest FTSE 100 group to be taken private, amid growing global competition for listings. Just last month, it emerged that as many as 20 FTSE 100 companies may move direct listings to New York. [...]
Has Nigel Farage peaked too soon? July 30, 2026 Whisper it but Nigel Farage and Reform UK’s ascendancy appears to be over, and the next election could be a straight Labour vs Conservatives fight, says Tom Harwood In May last year, when Keir Starmer dragged the nation’s political press along to a glass manufacturing centre in Warrington, everyone was a little baffled. While some [...]
Greggs eyes 3,500 sites – but its plans could prove to be flaky July 30, 2026 Sausage roll titan Greggs is already a fixture of almost every British high street, but it’s not done yet. Felix Armstrong chews through its latest expansion plans As Brits jet off to Spain for their summer holidays this year, they will be met with a familiar sight as they touch down at Tenerife airport. Beloved [...]
Michael Dell, Lord Johnson and the ‘gun to the head’ meeting that ended a £15bn AI project July 30, 2026 In December, billionaire Michael Dell opened an alarming email. “My trust in Mr Bellamy has been undermined by the way he has operated”, the email read, “and I cannot be certain the information he shared with you is accurate or complete”. The mysterious missive was sent by Patrick Hughes, the co-founder of a major new [...]
Everest Reports Second Quarter 2026 Results July 29, 2026 Annualized 14.2% Net Income ROE and 14.9% Net Operating Income ROE Annualized Total Shareholder Return of 16.8% $559 million of Net Income and Combined Ratio of 92.0% $317 million of Underwriting Income and Combined Ratio of 90.0% from our Core Businesses* Repurchased $395 million of Common Shares During the Quarter
Andab could be Talk of New York on Sussex Downs July 29, 2026 WE WILL take an early look at tFriday’s card where TALK OF NEW YORK is a hot favourite to win the Group Three HKJC World Pool Thoroughbred Stakes (2.25pm). This son of Wootton Bassett was an excellent third to Bow Echo and Gstaad in the Group One St James’s Palace Stakes last month. That form [...]
World Cup sponsors could pay price if Infantino’s Fifa sell-off goes ahead July 29, 2026 It’s not just match-going football fans who fear the financial ramifications of Fifa’s sell-off of commercial rights; World Cup sponsors could also find themselves paying more or getting less for their money, experts have warned. Sponsors currently contribute around a quarter of Fifa’s $15bn income over a four-year cycle and include some of the biggest [...]
AI firms targeting London’s rare book shops in ‘dystopian’ hunt for training data July 29, 2026 London’s rare book shops appear to have been targeted by AI companies searching for books to train their models, after court documents revealed Anthropic bought, scanned and destroyed millions of physical books as part of a controversial project to feed an insatiable demand for training data. One London-based seller of rare books told City AM [...]
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026 July 29, 2026 Superiority data from LATA, together with OPERA findings, add to the clinical and real-world evidence base for long-acting injectable Cabenuva Six-month follow-up CLARITY data further reinforce a more favourable injection experience with long-acting cabotegravir compared with lenacapavir after a single dose; additional studies showcase high real-world adherence and a preference for Apretude among previous oral PrEP users EXTEND 4M explores a new investigational intramuscular cabotegravir formulation dosed three times a year for HIV prevention, as part of broader long-acting pipeline data